OBJECTIVE:To investigate the mechanism of action of the Lingbao Huxin Dan(灵宝护心丹)in treating bradycardia arrhythmia with coronary heart disease(BACHD)by network pharmacology.METHODS:The active ingredients of the L...OBJECTIVE:To investigate the mechanism of action of the Lingbao Huxin Dan(灵宝护心丹)in treating bradycardia arrhythmia with coronary heart disease(BACHD)by network pharmacology.METHODS:The active ingredients of the Lingbao Huxin Dan were screened on the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and Bioinformatics tools designed for the analysis of molecular mechanisms of Chinese medicine platform;target prediction was conducted with the SwissTargetPrediction database,and Cytoscape 3.8 was used to construct a drug ingredient-target network.The Genecards,Online Mendelian Inheritance in Man,and DrugB ank databases were searched for disease targets.Venn plots were used to display the common targets of BA-CHD and active ingredients.The STRING platform was used to construct a protein-protein interaction network.The Metascape data platform was used for Gene Ontology(GO)enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analysis to construct a signaling pathway network of the active ingredients of the Lingbao Huxin Dan.RESULTS:There were 121 active ingredients,899 related targets,39 targets important in BA-CHD and 14 targets which intersected between the active ingredients and BA-CHD.There were 27 core therapeutic ingredients,153 biological processes,18 cell ingredients and 20 molecular functions obtained by GO enrichment analysis.The KEGG pathway analysis yielded 19 signaling pathways.CONCLUSION:RBA-CHD may treat BA-CHD by regulating adrenergic receptor beta-1,alpha 1-αadrenergic receptor,calcium voltage-gated channel subunit alpha1 C,alpha-1β-adrenergic receptor,nitric oxide synthase 2,beta-2 adrenergic receptor,voltagedependent calcium channel subunit alpha-2/delta-1,angiotensin-converting enzyme,Raf-1 proto-oncogene serine/threonine-protein kinase,and other targets,potentially by affecting adrenergic receptor binding and calcium channel opening,to regulate the activity of cardiomyocytes.展开更多
基金Training Project of National Administration of Traditional Chinese Medicine“Natural Training Project of Backbone of Traditional Chinese Medicine”(SATCM,No.2019-128)the Fundamental Research Funds for the Central Public Welfare Research Institutes:the Application of Panoramic Tissue Scanning and Quantitative Analysis Systems in the Research of Traditional Chinese Medicine for Disease Prevention and Treatment”(No.JBGS2021005)。
文摘OBJECTIVE:To investigate the mechanism of action of the Lingbao Huxin Dan(灵宝护心丹)in treating bradycardia arrhythmia with coronary heart disease(BACHD)by network pharmacology.METHODS:The active ingredients of the Lingbao Huxin Dan were screened on the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and Bioinformatics tools designed for the analysis of molecular mechanisms of Chinese medicine platform;target prediction was conducted with the SwissTargetPrediction database,and Cytoscape 3.8 was used to construct a drug ingredient-target network.The Genecards,Online Mendelian Inheritance in Man,and DrugB ank databases were searched for disease targets.Venn plots were used to display the common targets of BA-CHD and active ingredients.The STRING platform was used to construct a protein-protein interaction network.The Metascape data platform was used for Gene Ontology(GO)enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analysis to construct a signaling pathway network of the active ingredients of the Lingbao Huxin Dan.RESULTS:There were 121 active ingredients,899 related targets,39 targets important in BA-CHD and 14 targets which intersected between the active ingredients and BA-CHD.There were 27 core therapeutic ingredients,153 biological processes,18 cell ingredients and 20 molecular functions obtained by GO enrichment analysis.The KEGG pathway analysis yielded 19 signaling pathways.CONCLUSION:RBA-CHD may treat BA-CHD by regulating adrenergic receptor beta-1,alpha 1-αadrenergic receptor,calcium voltage-gated channel subunit alpha1 C,alpha-1β-adrenergic receptor,nitric oxide synthase 2,beta-2 adrenergic receptor,voltagedependent calcium channel subunit alpha-2/delta-1,angiotensin-converting enzyme,Raf-1 proto-oncogene serine/threonine-protein kinase,and other targets,potentially by affecting adrenergic receptor binding and calcium channel opening,to regulate the activity of cardiomyocytes.
